Mosaic quadrivalent influenza vaccine single nanoparticle characterization

• Published in: Scientific reports Vol. 14; no. 1; pp. 4534 - 12
• Main Authors: Yang, Rong Sylvie, Traver, Maria, Barefoot, Nathan, Stephens, Tyler, Alabanza, Casper, Manzella-Lapeira, Javier, Zou, Guozhang, Wolff, Jeremy, Li, Yile, Resto, Melissa, Shadrick, William, Yang, Yanhong, Ivleva, Vera B., Tsybovsky, Yaroslav, Carlton, Kevin, Brzostowski, Joseph, Gall, Jason G., Lei, Q. Paula
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.02.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/136; 631/1647; 631/535; Antigens; Clinical trials; ELISA; Fluorescence imaging; Fluorescence microscopy; Fluorescent labeling; Hemagglutinins; Humanities and Social Sciences; Immunogenicity; Influenza; Mass spectrometry; multidisciplinary; Nanoparticles; Population studies; Science; Science (multidisciplinary); Size-exclusion chromatography; TIRFM; Vaccines; Valency; Fluorescence imaging; Nanoparticle; TIRFM; Fluorescent labeling; Size-exclusion chromatography; Mass spectrometry; Influenza vaccine; ELISA
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-54876-2

Recent work by our laboratory and others indicates that co-display of multiple antigens on protein-based nanoparticles may be key to induce cross-reactive antibodies that provide broad protection against disease. To reach the ultimate goal of a universal vaccine for seasonal influenza, a mosaic influenza nanoparticle vaccine (FluMos-v1) was developed for clinical trial (NCT04896086). FluMos-v1 is unique in that it is designed to co-display four recently circulating haemagglutinin (HA) strains; however, current vaccine analysis techniques are limited to nanoparticle population analysis, thus, are unable to determine the valency of an individual nanoparticle. For the first time, we demonstrate by total internal reflection fluorescence microscopy and supportive physical–chemical methods that the co-display of four antigens is indeed achieved in single nanoparticles. Additionally, we have determined percentages of multivalent (mosaic) nanoparticles with four, three, or two HA proteins. The integrated imaging and physicochemical methods we have developed for single nanoparticle multivalency will serve to further understand immunogenicity data from our current FluMos-v1 clinical trial.